<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02054052</url>
  </required_header>
  <id_info>
    <org_study_id>GZTO1401</org_study_id>
    <nct_id>NCT02054052</nct_id>
  </id_info>
  <brief_title>Intrapleural Bevacizumab Injection for Malignant Effusion in Lung Cancer</brief_title>
  <official_title>Intrapleural Bevacizumab Injection for Treating Malignant Pleural or Pericardial Effusion in Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Haihong Yang, MD, Pricipal investigator</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangzhou Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Malignant pleural or pericardial effusion is common in lung cancer, and intrapleural drugs
      injection is important in the treatment. Non- cytotoxic drugs include those with a sclerosing
      effect that produces pleurodesis, which is easy to cause severe chest pain despite of no
      influence on the following chemotherapy. Tumor angiogenesis is important in producing MPE.
      Bevacizumab has been administrated locally in treating optic nerve sickness successfully by
      anti-VEGF mechanism. So we hypothesize that intrapleural bevacizumab is also effective in
      treating MPE.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inclusion Criteria:

        1. Histological or cytological diagnosis of non-small cell lung cancer.

        2. Cytological diagnosis of malignant pleural or pericardial effusion (MPE)

        3. Symptomatic MPE evaluated by researchers

        4. Unsuitable for or reject systemic therapy of tumor

        5. Continuous TKI treatment after TKI-resistance

        6. Estimated survival of more than 3 months. 7.18 years or older

      Exclusion Criteria:

        1. Current or recent (within 10 days prior to treatment) use the full amount of inhibition
           of platelet function, anticoagulants or thrombolytic therapy, which allows prophylactic
           anticoagulants

        2. Be allergic to bevacizumab

        3. Pregnant or lactating woman

        4. Pleural or pericardial infection
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">January 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lung cancer symptom</measure>
    <time_frame>Evaluated by lung cancer symptom scale 21-30 days after the treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>response rate</measure>
    <time_frame>Evaluate response rate 21-30 days after the treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>1 year after the treatment of MPE.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year after the treatment of MPE</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>one months after the treatment of MPE</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>Malignant Pleural Effusion</condition>
  <arm_group>
    <arm_group_label>Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bevacizumab 100 mg, intrapleural injection treating maliganant pleural or percardial effusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Bevacizumab 100 mg, intrapleural injection treating MPE after the drainage of MPE</description>
    <arm_group_label>Bevacizumab</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histological or cytological diagnosis of non-small cell lung cancer.

          2. Cytological diagnosis of malignant pleural or pericardial effusion (MPE)

          3. Symptomatic MPE evaluated by researchers

          4. Unsuitable for or reject systemic therapy of tumor

          5. Estimated survival of more than 3 months. 6.18 years or older

        Exclusion Criteria:

          1. Current or recent (within 10 days prior to treatment) use the full amount of
             inhibition of platelet function, anticoagulants or thrombolytic therapy, which allows
             prophylactic anticoagulants

          2. Be allergic to bevacizumab

          3. Pregnant or lactating woman

          4. Pleural or pericardial infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Haihong Yang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>the First Affiliated Hospital of Guangzhou MC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The First Affliliated Hospital of Guangzhou MC</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2014</study_first_submitted>
  <study_first_submitted_qc>February 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2014</study_first_posted>
  <last_update_submitted>December 12, 2017</last_update_submitted>
  <last_update_submitted_qc>December 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Guangzhou Medical University</investigator_affiliation>
    <investigator_full_name>Haihong Yang, MD, Pricipal investigator</investigator_full_name>
    <investigator_title>Deputy Chief Physician</investigator_title>
  </responsible_party>
  <keyword>non-small cell lung cancer</keyword>
  <keyword>malignant pleural effusion</keyword>
  <keyword>bevacizumab</keyword>
  <keyword>intrapleural injection</keyword>
  <keyword>pericardial effusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Pleural Effusion</mesh_term>
    <mesh_term>Pleural Effusion, Malignant</mesh_term>
    <mesh_term>Pericardial Effusion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

